The tech giant is set to report earnings as AI spending faces scrutiny. Here's what to expect.

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

InFlectis BioScience Announces Promising Results for IFB-088 in a Phase 2a Clinical Study in Bulbar-Onset ALS Patients ...

I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Optiscan said the collected images would be used to assess real ... and progress planning for the upcoming clinical phase to follow over coming months. The company said the staged approach to ...

A research team at UCLA has developed a deep learning-powered chemiluminescence vertical flow assay (CL-VFA) that brings ...

A few companies are in clinicals with novel approaches to heal an initial brain injury or minimize secondary damage. Slow progress may be more related to investors’ misperceptions of the topic than ...

A Manchester-based medtech company has secured funding from the GMC Life Sciences Fund By Praetura, and through NPIF II – Praetura Equity Finance, to continue scaling its ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Image: Adobe Stock. In a 36-month follow-up analysis from two phase 3 pivotal clinical trials, 70% of patients who underwent treatment with the iDose TR (travoprost intracameral implant ...